We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Dimethylamine Determination in Metformin HCI Drug Products
Product News

Dimethylamine Determination in Metformin HCI Drug Products

Dimethylamine Determination in Metformin HCI Drug Products
Product News

Dimethylamine Determination in Metformin HCI Drug Products


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Dimethylamine Determination in Metformin HCI Drug Products"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Thermo Fisher Scientific Inc. has developed a more sensitive method for detection of process-related impurity dimethylamine, a suspected human carcinogen, in metformin hydrochloride (HCI).

The method in Application Note 298: Determination of Dimethylamine in Metformin HCl Drug Product Using IC with Suppressed Conductivity Detection uses a Thermo Scientific Dionex IonPac CS19 cation-exchange analytical column with methanesulfonic acid eluent produced by the Dionex ICS ion chromatography (IC) system’s eluent generator.

Metformin HCI is the most widely prescribed orally administered drug for the treatment of type 2 diabetes and is also used for treatment of polycystic ovary syndrome.

To confirm the consistency of the manufacturing process, drug product manufacturers must monitor the level of impurities before commercial release of a drug product.

Advertisement